NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Harvard/NWBO workaround are hyperactivated dendritic cells (for Direct and L), which utilize manufacturing with inflammasomes in vitro. Patent if granted (I think it will be), goes out to 2040.

My guess is BP knows very well what the careful five years of preclinical research means.

That said, as FeMike also tends to think, it’s probably already all penciled in and awaiting a trigger event like approval of L.